Download PDF

Register to download the report. Already a member?

 
 
Sign Up

Or

63850 1504871583HCLSReviewHongKongSeptember2017.pdf
Energy Boardroom

Pharmacyclic’s Imbruvica Beats GSK’s Arzerra in Elderly CLL Patients

19.06.2014 / Thomson Reuters Blog

As the American Society of Clinical Oncology (ASCO) meeting entered day two, coffee-sipping attendees perked to a first-in-the-morning discussion of the phase III data with Pharmacyclics Inc.’s ibrutinib (branded Imbruvica) in relapsed chronic lymphocytic leukemia (CLL), the first time an oral drug has yielded survival improvement over standard therapy. CLL is usually treated with chemo-immunotherapy, […]

LATEST ISSUE

DOWNLOAD

Most Read

X
Download PDF

First Name:

Last Name:

Company:

Position:

Country:

Email: